The efficacy and safety of comfrey

Area of Science:

• Toxicology
• Pharmacology
• Herbal Medicine Research

Background:

• Herbal medications are increasingly recognized for both therapeutic benefits and potential health risks.
• Pyrrolizidine alkaloids (PAs) found in certain herbs are linked to significant toxicity, causing outbreaks when ingested via contaminated food or teas.
• Comfrey (Symphytum officinale) has been used traditionally for inflammatory conditions, but its use poses substantial health hazards.

Purpose of the Study:

• To highlight the serious health risks associated with comfrey consumption, particularly hepatic toxicity and carcinogenicity.
• To elucidate the mechanisms of toxicity involving pyrrolizidine alkaloids and their biotransformation.
• To discuss the clinical presentation and management of comfrey-induced liver injury.

Main Methods:

• Review of existing literature on pyrrolizidine alkaloid toxicity and comfrey's effects.
• Analysis of clinical cases and toxicological studies in humans and rodents.
• Examination of the biochemical pathways involved in alkaloid metabolism and DNA alkylation.

Main Results:

• Comfrey contains hepatotoxic pyrrolizidine alkaloids (e.g., lasiocarpine, symphytine) and their N-oxides, responsible for liver damage.
• The primary liver injury is veno-occlusive disease, leading to cirrhosis and liver failure.
• Toxic mechanisms involve biotransformation by hepatic enzymes into reactive pyrroles that alkylate cellular macromolecules, causing mutagenicity and carcinogenicity.

Conclusions:

• Comfrey (Symphytum officinale) poses significant risks of severe liver injury (veno-occlusive disease) and potential carcinogenicity due to its pyrrolizidine alkaloid content.
• Awareness and avoidance of comfrey intake are crucial; liver transplantation may be necessary in cases of imminent hepatic failure.
• Regulatory actions in Germany and Canada banning comfrey contrast with its continued availability in the US, raising public health concerns.